Yesterday
Downgrade
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to In Line from Outperform at Evercore ISI with analyst C.J. Muse saying he now believes "the lion's share" of the 5G smartphone upcycle is priced into the stock price and looking ahead Muse sees sentiment on Qualcomm related to Apple turning from 5G design win to potential insourcing. 2. JinkoSolar (JKS) downgraded to Neutral from Buy at Roth Capital with analyst Philip Shen saying JinkoSolar delivered a Q4 miss and weak Q1 guidance that he looks for the stock to be weak until the outlook for volume and margins improves, adding that it is unclear when that will happen. 3. GameStop (GME) downgraded to Sell from Hold at Ascendiant with analyst Edward Woo saying the Reddit trading surge "is likely to fade as "digital threats increases." 4. AstraZeneca (AZN) downgraded to Hold from Buy at Argus with analyst David Toung saying the rating change reflects his concerns that the company's COVID-19 vaccine AZD1222 may not receive emergency use authorization from the FDA due to safety issues emerging in Europe. 5. Knight-Swift (KNX) downgraded to Neutral from Positive at Susquehanna with analyst Bascome Majors citing valuation for his downgrade as he believes 2021 is likely the peak of this truckload cycle and his work suggests that all trucking-related stocks eventually de-rate cyclically. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Show Hide Related Items >> <<
03/29/21 FTC will not petition Supreme Court for review of Qualcomm case 03/16/21 InterDigital president, CEO William Merritt to retire, Liren Chen to succeed 03/10/21 Velodyne, Qualcomm, NavVis partner over smart city applications 03/10/21 Qualcomm increases dividend 5% to 68c per share 04/07/21 Knight-Swift increases driver pay and contractor rates 02/01/21 Knight-Swift acquires majority stake in mobile driver workflow firm Eleos 04/09/21 JinkoSolar falls -8.5% 04/09/21 JinkoSolar falls -8.3% 04/09/21 JinkoSolar drops 11% to $34.52 after mixed Q4 results 04/09/21 JinkoSolar sees FY21 total shipments 25GW-30GW 04/08/21 GameStop announces slate of director candidates for 2021 meeting 04/05/21 GameStop falls -7.6% 04/05/21 GameStop falls -10.4% 04/05/21 GameStop drops 11% to $169.94 after announcing 3.5M share equity offering 04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/12/21 Evercore ISI Evercore downgrades Qualcomm to In Line, sees most of 5G upside priced in 04/12/21 Evercore ISI Qualcomm downgraded to In Line from Outperform at Evercore ISI 03/24/21 Evercore ISI Intel price target raised to $75 from $68 at Evercore ISI 03/17/21 JPMorgan Apple chip transition an overhang on Qualcomm shares, says JPMorgan 04/12/21 Roth Capital JinkoSolar downgraded to Neutral from Buy at Roth Capital 04/12/21 Roth Capital JinkoSolar downgraded to Neutral from Buy at Roth Capital 02/08/21 Roth Capital Bill could be 'meaningful positive' for solar stocks, says Roth Capital 01/04/21 Goldman Sachs JinkoSolar price target raised to $39 from $34 at Goldman Sachs 04/12/21 Ascendiant GameStop downgraded to Sell from Hold at Ascendiant 04/06/21 BofA BofA keeps $10 target on GameStop despite 'positive' funding news 04/05/21 Telsey Advisory Telsey keeps Underperform rating on GameStop after Q1 update, ATM program bump 03/24/21 Fly Intel: Top five analyst downgrades 04/12/21 B. Riley B. Riley calls Agenus the next Seagen, reiterates $8 target 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 04/12/21 Susquehanna Knight-Swift downgraded to Neutral at Susquehanna 04/12/21 Susquehanna Knight-Swift downgraded to Neutral from Positive at Susquehanna 03/26/21 Vertical Research Knight-Swift reinstated with a Buy at Vertical Research 03/11/21 UBS Knight-Swift downgraded to Neutral from Buy at UBS 02/03/21 Qualcomm sees Q2 EPS $1.55-$1.75, consensus $1.57 02/03/21 Qualcomm reports Q1 EPS $2.17, consensus $2.10 02/03/21 Notable companies reporting after market close 11/04/20 Qualcomm sees Q1 adjusted EPS $1.95-$2.15, consensus $1.68 01/27/21 Knight-Swift reports Q4 adjusted EPS 94c, consensus 91c 01/26/21 Notable companies reporting before tomorrow's open 10/21/20 Knight-Swift sees FY21 adj. EPS $3.20-$3.40, consensus $2.83 04/09/21 JinkoSolar sees Q1 revenue $1.18B-$1.3B, consensus $1.31B 04/09/21 JinkoSolar reports Q4 adjusted EPS 11c, consensus 37c 12/07/20 JinkoSolar sees Q4 revenue $1.31B-$1.43B. consensus $1.52B 12/07/20 JinkoSolar reports Q3 EPS $1.06, consensus 85c 04/05/21 GameStop reports preliminary sales QTD up about 9% y/y 03/23/21 GameStop reports Q4 adjusted EPS $1.34, consensus $1.35 03/23/21 Notable companies reporting after market close 12/08/20 GameStop reports Q3 adj. EPS (53c), consensus (85c) 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 04/06/21 Facebook, Apple and Niantic see a future in augmented -reality glasses, WSJ says 03/24/21 Qualcomm to release game-console in 2022, Android Police reports 03/17/21 FTC officials unlikely to file Supreme Court appeal in Qualcomm case, WSJ says 03/17/21 FTC unlikely to file Supreme Court appeal in Qualcomm antitrust case, WSJ says 01/08/21 JinkoSolar, Daqo named in report on companies tied to forced labor use, NYT says 03/31/21 Fortnite maker Epic Games in talks for $1.7B in fundraising, Bloomberg reports 03/16/21 Bill Gross says he made $10M shorting GameStop, Bloomberg says 03/16/21 Bill Gross says still short GameStop, Bloomberg reports 03/13/21 Retro stocks suddenly hot, Barron's says 04/09/21 AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 04/12/21 Tesla, Chipotle upgrades among today's top calls on Wall Street 04/07/21 #SocialStocks: AR glasses seen as future of tech 03/24/21 Street Fight: Analysts diverge on Intel following 'Unleashed' event 03/04/21 Snowflake, Qualcomm upgrades among today's top calls on Wall Street 04/09/21 Fly Intel: Wall Street's top stories for Friday 04/09/21 Fly Intel: Wall Street's top stories at midday 04/09/21 Fly Intel: Pre-market Movers 02/13/21 Charged: Tesla discloses $1.5B bitcoin investment 04/08/21 Fly Intel: Wall Street's top stories for Thursday 04/08/21 Fly Intel: Wall Street's top stories at midday 04/08/21 GameStop back in spotlight after nominating Cohen as chairman 04/08/21 Fly Intel: Pre-market Movers 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 04/05/21 Unusually active option classes on open April 5th 12/07/20 Qualcomm call buyer realizes 32% same-day gains 12/04/20 Qualcomm call volume above normal and directionally bullish 11/11/20 Qualcomm call volume above normal and directionally bullish 04/07/21 JinkoSolar put volume heavy and directionally bearish 03/24/21 JinkoSolar put volume heavy and directionally bearish 03/09/21 JinkoSolar call volume above normal and directionally bullish 02/26/21 JinkoSolar call volume above normal and directionally bullish 03/23/21 GameStop options imply 45.0% move in share price post-earnings 03/12/21 Notable open interest changes for March 12th 03/11/21 Notable open interest changes for March 11th 03/11/21 Largest borrow rate increases among liquid names 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish
Recommendations
B. Riley analyst Mayank…
B. Riley analyst Mayank Mamtani reiterates a Buy rating on Agenus (AGEN) with an $8 price target coming away from American Association for Cancer Research annual meeting. The analyst gained "incremental visibility" into the potential of Agenus' immune-oncology platform, which he says is "leapfrogging industry bellwethers" like Merck (MRK), Bristol-Myers (BMY), AstraZeneca (AZ) and Roche (Roche). Mamtani believes Agenus is the next Seagen (SGEN). The analyst highlights the "breakthrough potential" of Agenus' pipeline as incremental clinical data matures from AGEN1181. This is similar to what was observed with Seagen originally when it was primarily an Adcetris-centric story with substantial value ascribed in recent years with strong execution across multiple high-value programs towards registration, Mamtani tells investors in a research note.
Show Hide Related Items >> <<
04/09/21 Seagen, Genmab say FDA accepts BLA for tisotumab vedotin for priority review 03/26/21 Astellas Pharma, Seagen announce enfortumab vedotin MAA accepted by EMA 03/25/21 Pieris amend immuno-oncology pact with Seagen 03/05/21 Seagen recommends shareholders reject TRC Capital mini-tender offer 04/12/21 IGM Biosciences appoints George Gauthier as chief commercial officer 04/05/21 Prothena appoints Hideki Garren as chief medical officer 04/01/21 PTC Therapeutics to receive $20M commercial milestone payment from Roche 03/30/21 Roche announces European Commission approval of Evrysdi 04/08/21 Immutep achieves fast track designation from FDA for Efti 04/08/21 Merck says Phase 3 KEYNOTE-564 trial met primary endpoint 04/07/21 Alkermes announces nemvaleukin trial collaboration, supply agreement with Merck 04/07/21 IMV Inc. enters agreement with Merck to initiate maveropepimut-S, Keytruda trial 04/11/21 Bristol-Myers announces results from CheckMate -816 study 04/08/21 Bristol-Myers reports 'positive' results from Phase 3 CheckMate -648 trial 04/01/21 Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers 03/30/21 Huyabio International enters clinical collaboration agreement with Bristol-Myers 04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/11/21 Agenus presents new clinical data on AGEN1181 at AACR Meeting 03/10/21 Agenus to present new clinical data on AGEN1181 at AACR 02/09/21 Agenus names Andy Hurley chief commercial officer 02/09/21 Agenus announces new responses for AGEN1181 09/22/20 B. Riley B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases 09/18/20 Jefferies Agenus price target raised to $8 from $5 at Jefferies 04/08/21 Alliance Global Partners Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive 04/08/21 H.C. Wainwright Alkermes collaboration not as big as investors wanted, says H.C. Wainwright 04/07/21 Mizuho Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin 04/06/21 RBC Capital Merck transferred with a Sector Perform at RBC Capital 03/08/21 BofA Gartner added to US 1 List, Bristol-Myers removed at BofA 02/12/21 Morgan Stanley Amgen court decision may have readthrough for Gilead, says Morgan Stanley 02/02/21 BTIG Prothena upgraded to Buy at BTIG on birtamimab 'revival' 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/29/21 RBC Capital PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation 03/25/21 Wedbush iTeos Therapeutics price target raised to $52 from $46 at Wedbush 03/23/21 Truist Truist sees mixed readthroughs to Wave's toplines from competitor HD setback 03/23/21 BMO Capital Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital 03/30/21 Credit Suisse Seagen initiated with a Neutral at Credit Suisse 03/30/21 Credit Suisse Seagen initiated with a Neutral at Credit Suisse 02/16/21 RBC Capital Seagen price target lowered to $169 from $186 at RBC Capital 02/12/21 Barclays Seagen price target lowered to $168 from $177 at Barclays 02/11/21 Seagen reports Q4 EPS 90c, consensus 86c 10/29/20 Seagen reports Q3 EPS $3.50 vs. (55c) last year 02/04/21 Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 02/04/21 Merck sees FY21 adjusted EPS $6.48-$6.68, consensus $6.41 02/04/21 Merck reports Q4 adjusted EPS $1.32, consensus $1.38 02/03/21 Notable companies reporting before tomorrow's open 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 03/15/21 Agenus reports Q4 EPS (20c), consensus (22c) 10/29/20 Agenus reports Q3 EPS (28c), consensus (26c) 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 02/11/21 Roche arthritis drug reduced Covid deaths in study, Reuters reports 03/15/21 Gilead, Merck to develop long-acting HIV therapy treatment, WSJ reports 03/10/21 Biden to announce U.S. buying 100M more doses of J&J vaccine, NBC reports 03/08/21 Biden to meet with CEOs of J&J, Merck at White House, Reuters reports 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports 04/01/21 Accidental disclosure show Bristol-Myers, I.R.S. $1B tax fight, NY Times reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 04/09/21 AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 02/11/21 Fly Intel: After-Hours Movers 10/29/20 Fly Intel: After-Hours Movers 03/23/21 Fly Intel: Wall Street's top stories for Tuesday 03/23/21 Ionis Pharmaceuticals slides as Wall Street digests HD program setback 03/23/21 Fly Intel: Wall Street's top stories at midday 03/23/21 Fly Intel: Pre-market Movers 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday 03/29/21 Fly Intel: Pre-market Movers 02/09/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks 11/21/20 Week in review: How Trump's policies moved stocks 04/09/21 Fly Intel: Wall Street's top stories for Friday 04/09/21 Fly Intel: Wall Street's top stories at midday 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 03/02/21 Unusually active option classes on open March 2nd 02/17/21 Merck call volume above normal and directionally bullish 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish 04/07/21 Unusually active option classes on open April 7th 01/20/21 Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish
Downgrade
Argus analyst David Toung…
Argus analyst David Toung downgraded AstraZeneca to Hold from Buy. The rating change reflects his concerns that the company's COVID-19 vaccine AZD1222 may not receive emergency use authorization from the FDA due to safety issues emerging in Europe, the analyst tells investors in a research note, stating that the blood clot issue has led governments in the U.K. and many European countries to restrict the use of AZD1222. Toung further notes that manufacturing errors that led to AstraZeneca discarding millions of doses compound the impact on public confidence in AZD1222 and, in turn, on potential revenue and earnings from the vaccine.
Show Hide Related Items >> <<
04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 04/09/21 AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 04/09/21 Fly Intel: Wall Street's top stories for Friday 04/09/21 Fly Intel: Wall Street's top stories at midday 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish
Hot Stocks
Zentalis Pharmaceuticals…
Zentalis Pharmaceuticals (ZNTL) announced a clinical collaboration agreement with GlaxoSmithKline (GSK) in which Zentalis will evaluate the combination of ZN-c3, Zentalis' oral WEE1 inhibitor product candidate, and ZEJULA, GSK's poly polymerase inhibitor, in patients with advanced epithelial ovarian cancer. Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies. Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study with GSK providing all required doses of niraparib. Zentalis maintains full ownership of ZN-c3.
Show Hide Related Items >> <<
04/11/21 Zentalis announces initial data on ZN-c3 in patients with advanced solid tumors 03/25/21 Zentalis expects cash to fund requirements into 2023 02/10/21 Zentalis appoints Enoch Kariuki to board of directors 01/06/21 Zentalis initiates patient dosing in three clinical trials 04/01/21 Lannett submits ANDA for generic equivalent of GlaxoSmithKline's Advair 04/01/21 Royalty Pharma acquires royalty interest in cabozantinib from GlaxoSmithKline 03/29/21 GlaxoSmithKline to support manufacture of Novavax' COVID-19 vaccine 03/29/21 GlaxoSmithKline to support manufacture of Novavax' COVID-19 vaccine in UK 03/26/21 H.C. Wainwright Zentalis price target raised to $65 from $43 at H.C. Wainwright 01/19/21 Wedbush Zentalis initiated with an Outperform at Wedbush 09/28/20 Cantor Fitzgerald Cantor starts 'underappreciated' Zentalis with Overweight, $44 target 09/28/20 Cantor Fitzgerald Zentalis initiated with an Overweight at Cantor Fitzgerald 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink 03/08/21 JPMorgan JPMorgan double downgrades AnaptysBio back to Underweight after trial miss 03/25/21 Zentalis reports Q4 EPS ($1.01), consensus (95c) 11/09/20 Zentalis reports Q3 EPS (91c), consensus (81c) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
Downgrade
Argus analyst David Toung…
Argus analyst David Toung downgraded AstraZeneca to Hold from Buy.
Show Hide Related Items >> <<
04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 03/18/21 Deutsche Bank AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 04/09/21 AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 04/09/21 Fly Intel: Wall Street's top stories for Friday 04/09/21 Fly Intel: Wall Street's top stories at midday 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish
Friday
On The Fly
The major averages closed…
Show Hide Related Items >> <<
04/08/21 Provention Bio trading resumes 04/08/21 Provention Bio receives FDA notification of deficiencies in BLA for teplizumab 04/08/21 Provention Bio trading halted, news pending 03/03/21 Provention Bio's teplizumab shows efficacy in delaying type 1 diabetes 04/09/21 Pfizer, BioNTech seek expansion of vaccine EUA to include 12-15 year olds 04/08/21 Celcuity announces gedatolisib licensing agreement with Pfizer 04/07/21 Pfizer's NDA for abrocitinib in dermatitis granted extended review by FDA 04/09/21 Levi Strauss rises 7.7% 04/08/21 Levi Strauss CEO: The brand is hot 04/08/21 Levi Strauss jumps about 8% to $27 per share after Q1 beat, raised outlook 04/08/21 Levi Strauss raises quarterly dividend to 6c from 4c per share 04/05/21 Cidara, Janssen enter agreement to develop, commercialize AVCs 04/05/21 J&J assumes responsibility of vaccine manufacturing at Emergent facility 04/05/21 Emergent BioSolutions receives modified $23M task order from BARDA 04/01/21 SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study 04/09/21 JinkoSolar falls -8.5% 04/09/21 JinkoSolar falls -8.3% 04/09/21 JinkoSolar drops 11% to $34.52 after mixed Q4 results 04/09/21 JinkoSolar sees FY21 total shipments 25GW-30GW $23.30 / +2.605 (+12.59%)
04/09/21 FuboTV rises 17.5% 04/09/21 FuboTV rises 7.6% 04/08/21 FuboTV acquires streaming rights to some Qatar World Cup 2022 Qualifying matches 03/31/21 FuboTV signs carriage agreement with Marquee Sports Network 04/08/21 Crown to sell 80% European tinplate unit to KPS for EU1.9B 02/25/21 Crown Holdings announces $1.5B share repurchase program 02/16/21 Greenlight Capital buys FuboTV and Danimer Scientific, exits Intel 02/09/21 Crown Holdings CEO says '-positioned for an excellent 2021' 04/01/21 Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study 03/31/21 BioNTech, Pfizer: 'Positive' results of COVID-19 vaccine study in adolescents 03/30/21 BioNTech says evaluation of safety of third BNT162b2 dose initiated 04/09/21 Boeing recommends 16 customers address potential issue for some 737 MAX jets 04/08/21 Air Transport Services delivers third Boeing 767 freighter to Raya Airways 04/08/21 Air Lease delivers one new Boeing 737-8 aircraft to Belavia-Belarusian Airlines 04/07/21 AerCap says leased, purchased, sold 70 aircraft in Q1 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 EMA concludes blood clots 'very rare' side effect of Astra vaccine $3,371.40 / +73.69 (+2.23%)
04/09/21 Amazon says less than 16% of employees at BHM1 voted to join RWDSU union 04/08/21 Amazon adds 720p streaming to its Luna cloud gaming service 04/08/21 Amazon AWS announces general availability of Amazon lookout for equipment 04/06/21 Amazon's Bezos supports raise in U.S. corporate taxes amid infrastructure spend 04/09/21 Baird Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets 03/29/21 Goldman Sachs Boeing resuming 787 deliveries removes overhang, says Goldman Sachs 03/19/21 Susquehanna Boeing price target raised to $300 from $250 at Susquehanna 03/15/21 Morgan Stanley Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley $3,371.40 / +73.69 (+2.23%)
04/05/21 Evercore ISI Amazon.com assumed with an Outperform at Evercore ISI 04/01/21 Wedbush Microsoft gets another major win within the beltway, says Wedbush 04/01/21 Credit Suisse Ubiquiti price target lowered to $126 from $157 at Credit Suisse 03/31/21 Wolfe Research Amazon.com assumed with an Outperform at Wolfe Research 04/09/21 Goldman Sachs Crown Holdings initiated with a Neutral at Goldman Sachs 02/11/21 Citi Crown Holdings price target raised to $125 from $117 at Citi 02/11/21 Barclays Crown Holdings price target raised to $122 from $103 at Barclays 01/26/21 BMO Capital Sonoco Products downgraded to Market Perform from Outperform at BMO Capital 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 03/18/21 Deutsche Bank AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 04/09/21 Pfizer to host conference call 04/06/21 RBC Capital Pfizer transferred with a Sector Perform at RBC Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley $23.30 / +2.605 (+12.59%)
04/05/21 Evercore ISI FuboTV assumed with an Outperform at Evercore ISI 03/29/21 Needham Needham lays out 'bull case' on 'inexpensive' FuboTV shares 03/09/21 Oppenheimer FuboTV price target lowered to $35 from $45 at Oppenheimer 03/08/21 Alliance Global Partners Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners 04/09/21 UBS Levi Strauss price target raised to $34 from $29 at UBS 04/09/21 Citi Levi Strauss price target raised to $29 from $25 at Citi 01/27/21 Citi Levi Strauss price target raised to $25 from $19 at Citi 01/07/21 JPMorgan Levi Strauss price target raised to $21 from $18 at JPMorgan 04/09/21 SVB Leerink Provention Bio price target lowered to $16 from $26 at SVB Leerink 04/09/21 RBC Capital Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice 04/09/21 Cantor Fitzgerald Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald 04/09/21 RBC Capital Provention Bio downgraded to Sector Perform from Outperform at RBC Capital 02/08/21 Roth Capital Bill could be 'meaningful positive' for solar stocks, says Roth Capital 01/04/21 Goldman Sachs JinkoSolar price target raised to $39 from $34 at Goldman Sachs 12/30/20 GLJ Research GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares 12/21/20 Roth Capital ITC/PTC extensions likely included in COVID relief package, says Roth Capital 02/25/21 Provention Bio reports Q4 EPS (58c), consensus (50c) 11/05/20 Provention Bio reports Q3 EPS (56c), consensus (43c) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 04/08/21 Levi Strauss raises first half EPS view to 41c-42c, consensus 30c 04/08/21 Levi Strauss reports Q1 EPS 34c, consensus 25c 01/27/21 Levi Strauss reports Q4 EPS 20c, consensus 15c 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 04/09/21 JinkoSolar sees Q1 revenue $1.18B-$1.3B, consensus $1.31B 04/09/21 JinkoSolar reports Q4 adjusted EPS 11c, consensus 37c 12/07/20 JinkoSolar sees Q4 revenue $1.31B-$1.43B. consensus $1.52B 12/07/20 JinkoSolar reports Q3 EPS $1.06, consensus 85c $23.30 / +2.605 (+12.59%)
03/02/21 FuboTV raises FY21 revenue view to $460M-$470M from $415M-$435M 03/02/21 FuboTV sees Q1 revenue $101M-$103M, consensus $99.36M 03/02/21 FuboTV reports Q4 EPS ($2.47), consensus (73c) 01/05/21 FuboTV reports preliminary Q4 revenue $94M-$98M, consensus $87.36M 02/09/21 Crown Holdings sees FY21 adjusted EPS $6.60-$6.80, consensus $6.38 02/09/21 Crown Holdings sees Q1 adjusted EPS $1.35-$1.40, consensus $1.26 02/09/21 Crown Holdings reports Q4 adjusted EPS $1.50, consensus $1.27 10/19/20 Crown Holdings sees FY20 adjusted EPS $5.65-$5.70, consensus $5.18 01/27/21 Boeing reports Q4 core EPS ($15.25), consensus ($1.80) 01/26/21 Notable companies reporting before tomorrow's open 10/28/20 Boeing reports Q3 core EPS ($1.39), consensus ($2.32) 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage $3,371.40 / +73.69 (+2.23%)
02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet 02/02/21 Amazon.com sees Q1 revenue $100B-$106B , consensus $95.69B 02/02/21 Amazon.com reports Q4 EPS $14.09, consensus $7.23 02/02/21 Notable companies reporting after market close
On The Fly
Show Hide Related Items >> <<
04/08/21 Provention Bio trading resumes 04/08/21 Provention Bio receives FDA notification of deficiencies in BLA for teplizumab 04/08/21 Provention Bio trading halted, news pending 03/03/21 Provention Bio's teplizumab shows efficacy in delaying type 1 diabetes 04/09/21 Levi Strauss rises 7.7% 04/08/21 Levi Strauss CEO: The brand is hot 04/08/21 Levi Strauss jumps about 8% to $27 per share after Q1 beat, raised outlook 04/08/21 Levi Strauss raises quarterly dividend to 6c from 4c per share 04/05/21 Cidara, Janssen enter agreement to develop, commercialize AVCs 04/05/21 J&J assumes responsibility of vaccine manufacturing at Emergent facility 04/05/21 Emergent BioSolutions receives modified $23M task order from BARDA 04/01/21 SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study 04/09/21 JinkoSolar falls -8.5% 04/09/21 JinkoSolar falls -8.3% 04/09/21 JinkoSolar drops 11% to $34.52 after mixed Q4 results 04/09/21 JinkoSolar sees FY21 total shipments 25GW-30GW 04/08/21 Crown to sell 80% European tinplate unit to KPS for EU1.9B 02/25/21 Crown Holdings announces $1.5B share repurchase program 02/16/21 Greenlight Capital buys FuboTV and Danimer Scientific, exits Intel 02/09/21 Crown Holdings CEO says '-positioned for an excellent 2021' 04/09/21 Boeing recommends 16 customers address potential issue for some 737 MAX jets 04/08/21 Air Transport Services delivers third Boeing 767 freighter to Raya Airways 04/08/21 Air Lease delivers one new Boeing 737-8 aircraft to Belavia-Belarusian Airlines 04/07/21 AerCap says leased, purchased, sold 70 aircraft in Q1 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 EMA concludes blood clots 'very rare' side effect of Astra vaccine $3,352.25 / +54.54 (+1.65%)
04/09/21 Amazon says less than 16% of employees at BHM1 voted to join RWDSU union 04/08/21 Amazon adds 720p streaming to its Luna cloud gaming service 04/08/21 Amazon AWS announces general availability of Amazon lookout for equipment 04/06/21 Amazon's Bezos supports raise in U.S. corporate taxes amid infrastructure spend 04/09/21 Affimed N.V. announces clinical data from cbNK cells with AFM13 study 03/31/21 Affimed N.V,'s IND application for antitumor combination granted FDA clearance. 03/10/21 Affimed N.V. to continue enrollment in AFM13 study after positive interim data 02/08/21 Point72 Asset Management reports 5.0% passive stake in Affimed N.V. 04/09/21 Baird Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets 03/29/21 Goldman Sachs Boeing resuming 787 deliveries removes overhang, says Goldman Sachs 03/19/21 Susquehanna Boeing price target raised to $300 from $250 at Susquehanna 03/15/21 Morgan Stanley Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley $3,352.25 / +54.54 (+1.65%)
04/05/21 Evercore ISI Amazon.com assumed with an Outperform at Evercore ISI 04/01/21 Wedbush Microsoft gets another major win within the beltway, says Wedbush 04/01/21 Credit Suisse Ubiquiti price target lowered to $126 from $157 at Credit Suisse 03/31/21 Wolfe Research Amazon.com assumed with an Outperform at Wolfe Research 04/09/21 Goldman Sachs Crown Holdings initiated with a Neutral at Goldman Sachs 02/11/21 Citi Crown Holdings price target raised to $125 from $117 at Citi 02/11/21 Barclays Crown Holdings price target raised to $122 from $103 at Barclays 01/26/21 BMO Capital Sonoco Products downgraded to Market Perform from Outperform at BMO Capital 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 03/18/21 Deutsche Bank AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 03/30/21 Credit Suisse Affimed N.V. initiated with an Outperform at Credit Suisse 03/30/21 Credit Suisse Affimed N.V. initiated with an Outperform at Credit Suisse 03/24/21 Wells Fargo Affimed N.V. price target raised to $15 from $10 at Wells Fargo 03/10/21 BMO Capital BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis 04/09/21 UBS Levi Strauss price target raised to $34 from $29 at UBS 04/09/21 Citi Levi Strauss price target raised to $29 from $25 at Citi 01/27/21 Citi Levi Strauss price target raised to $25 from $19 at Citi 01/07/21 JPMorgan Levi Strauss price target raised to $21 from $18 at JPMorgan 04/09/21 SVB Leerink Provention Bio price target lowered to $16 from $26 at SVB Leerink 04/09/21 RBC Capital Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice 04/09/21 Cantor Fitzgerald Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald 04/09/21 RBC Capital Provention Bio downgraded to Sector Perform from Outperform at RBC Capital 02/08/21 Roth Capital Bill could be 'meaningful positive' for solar stocks, says Roth Capital 01/04/21 Goldman Sachs JinkoSolar price target raised to $39 from $34 at Goldman Sachs 12/30/20 GLJ Research GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares 12/21/20 Roth Capital ITC/PTC extensions likely included in COVID relief package, says Roth Capital 02/25/21 Provention Bio reports Q4 EPS (58c), consensus (50c) 11/05/20 Provention Bio reports Q3 EPS (56c), consensus (43c) 04/08/21 Levi Strauss raises first half EPS view to 41c-42c, consensus 30c 04/08/21 Levi Strauss reports Q1 EPS 34c, consensus 25c 01/27/21 Levi Strauss reports Q4 EPS 20c, consensus 15c 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 04/09/21 JinkoSolar sees Q1 revenue $1.18B-$1.3B, consensus $1.31B 04/09/21 JinkoSolar reports Q4 adjusted EPS 11c, consensus 37c 12/07/20 JinkoSolar sees Q4 revenue $1.31B-$1.43B. consensus $1.52B 12/07/20 JinkoSolar reports Q3 EPS $1.06, consensus 85c 02/09/21 Crown Holdings sees FY21 adjusted EPS $6.60-$6.80, consensus $6.38 02/09/21 Crown Holdings sees Q1 adjusted EPS $1.35-$1.40, consensus $1.26 02/09/21 Crown Holdings reports Q4 adjusted EPS $1.50, consensus $1.27 10/19/20 Crown Holdings sees FY20 adjusted EPS $5.65-$5.70, consensus $5.18 01/27/21 Boeing reports Q4 core EPS ($15.25), consensus ($1.80) 01/26/21 Notable companies reporting before tomorrow's open 10/28/20 Boeing reports Q3 core EPS ($1.39), consensus ($2.32) 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage $3,352.25 / +54.54 (+1.65%)
02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet 02/02/21 Amazon.com sees Q1 revenue $100B-$106B , consensus $95.69B 02/02/21 Amazon.com reports Q4 EPS $14.09, consensus $7.23 02/02/21 Notable companies reporting after market close
Periodicals
AstraZeneca has reduced…
AstraZeneca has reduced the number of COVID-19 vaccine doses it will deliver to EU nations this week by nearly half, the Finiancial Times' Donato Paolo Mancini, Hannah Kuchler, and Michael Peel reports. The company now anticipates delivering roughly 1.3M shots to the EU's 27 nations, plus Iceland and Norway, down from the 2.6M target it established last month, the authors say, citing documents seen by the FT. The reduction is equivalent to a 49% slashing and is evenly distributed across member states, the authors note. Reference Link
Show Hide Related Items >> <<
04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 EMA concludes blood clots 'very rare' side effect of Astra vaccine 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 03/18/21 Deutsche Bank AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 04/07/21 Italy recommends AstraZeneca vaccine only for over-60s, Reuters reports 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish
Periodicals
The European Medicines…
The European Medicines Agency is evaluating reports of a bleeding condition in people after receiving AstraZeneca's (AZN) COVID-19 vaccine as well as reviewing Johnson & Johnson's (JNJ) shot over reports of rare blood clots, Reuters' reports, citing the agency. The EMA said four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine and five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported. Reference Link
Show Hide Related Items >> <<
04/05/21 Cidara, Janssen enter agreement to develop, commercialize AVCs 04/05/21 J&J assumes responsibility of vaccine manufacturing at Emergent facility 04/05/21 Emergent BioSolutions receives modified $23M task order from BARDA 04/01/21 SpringsWorks Therapeutics doses first patient in Phase 1b nirogacestat study 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 04/07/21 MHRA issues new advice, sees possible link between AstraZeneca vaccine and clots 04/07/21 U.K. offers Pfizer, Moderna vaccine to those under 30 with risk conditions 04/07/21 EMA concludes blood clots 'very rare' side effect of Astra vaccine 04/07/21 Citi FibroGen update creates only 'bad optic' for AstraZeneca, says Citi 03/26/21 Piper Sandler AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler 03/23/21 Societe Generale AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale 03/18/21 Deutsche Bank AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 04/08/21 North Carolina halts Johnson&Johnson COVID shots on adverse reactions, AP says 04/08/21 Mass vaccination site closed temporarily following adverse reactions, WSJ says 04/06/21 Biden to say all U.S. adults should be vaccine-eligible by April 19, WSJ says 04/08/21 Spain recommends AstraZeneca vaccine for over-60s only, FT reports 04/08/21 Official warned that Emergent plant had to be 'monitored closely,' NYT reports 04/07/21 Italy recommends AstraZeneca vaccine only for over-60s, Reuters reports 04/07/21 Italy recommends Astra COVID vaccine use for over 60 years old, Bloomberg says 04/05/21 Fly Intel: Wall Street's top stories for Monday 04/05/21 Fly Intel: Wall Street's top stories at midday 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 04/01/21 Fly Intel: Wall Street's top stories for Thursday 04/01/21 Fly Intel: Wall Street's top stories at midday 04/01/21 Unusually active option classes on open April 1st 03/01/21 Unusually active option classes on open March 1st 01/26/21 Early notable gainers among liquid option names on January 26th 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish